Intensity Therapeutics (INTS) vs Lisata Therapeutics (LSTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Intensity Therapeutics (INTS) has outperformed Lisata Therapeutics (LSTA) over the past year, losing 48.4% versus a loss of 52.6%. Lisata Therapeutics is the larger company by market cap ($13.0 million vs $12.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INTS | LSTA |
|---|---|---|
| Share price | $3.68 | $1.20 |
| Market cap | $12.01M | $12.96M |
| 1-day change | -3.16% | +2.56% |
| YTD return | -64.10% | -35.48% |
| 1-year return | -48.35% | -52.57% |
| 5-year return | — | -93.44% |
| EPS (TTM) | $-3.89 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.50 | $5.07 |
| 52-week low | $3.21 | $0.99 |
| Distance from 52-week high | -91.54% | -76.33% |
| Analyst consensus | none | none |
| Avg. price target upside | +425.27% | — |
| Average volume | 25.93K | 291.91K |
| Shares outstanding | 3.26M | 10.80M |
| Employees | 5 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Intensity Therapeutics
INTS stock →Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
INTS vs LSTA FAQ
Which is bigger, Intensity Therapeutics or Lisata Therapeutics?
Lisata Therapeutics (LSTA) is larger, with a market capitalization of $12.96M compared with $12.01M for Intensity Therapeutics (INTS).
Which stock has performed better over the past year, INTS or LSTA?
INTS returned -48.35% over the past 12 months, compared with -52.57% for LSTA (price return, excluding dividends). Past performance does not predict future results.
Are Intensity Therapeutics and Lisata Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Intensity Therapeutics and Biotechnology: Pharmaceutical Preparations for Lisata Therapeutics.